Researchers have defined urinary steroid metabolite levels that indicate inadequate and excessive adrenal suppression for children with congenital adrenal hyperplasia undergoing glucocorticoid treatment.
The 5-year outcomes of the Teen-LABS cohort show that adolescents who undergo bariatric surgery have a good chance of achieving diabetes remission, but may require more reoperations than adult patients.
The randomised Ellipse trial has demonstrated significant blood glucose reductions with the glucagon-like peptide-1 receptor agonist liraglutide in children and adolescents with type 2 diabetes already taking metformin.
Data from clinical practice support the option of adding gonadotrophin-releasing hormone analogue to growth hormone therapy in some clinical situations to extend the treatment window and optimise final height in children with idiopathic short stature.
A study of patients with mutations or terminal deletions in the insulin-like growth factor 1 receptor gene shows that the majority are small for gestational age, short and microcephalic, with an elevated serum IGF-1 level.
Research shows that growth hormone deficiency and central precocious puberty can occur in children several years after traumatic brain injury (TBI), even among those with normal pituitary function 1 year after the event.
Basal adrenal androgen levels can help identify girls with non-classical congenital adrenal hyperplasia who present as central precocious puberty, but adrenocorticotrophic hormone stimulation may be needed for a firm diagnosis, say researchers.